Why Replimune Is Up 15.5% After a 10-3 FDA Panel Win on RP1-and Why the Clock Starts Now

Why the 10-3 FDA panel vote matters now

After a 10-3 advisory panel vote finding the IGNYTE data evaluable and clinically meaningful, RP1 looks less like an early-stage story and more like a near-term approval candidate. The panel was reviewing Replimune's BLA for RP1 plus nivolumab in advanced melanoma after prior anti-PD-1 failure, and the next key checkpoint is the FDA's Aug. 2 action date. That is the clearest reason the stock is moving now.

What the panel actually changed

FDA reviewers had raised doubts about the single-arm design and whether the data cleanly separated RP1's effect from nivolumab. The outside panel largely pushed back, voting 10-3 that the efficacy results are evaluable and clinically meaningful. That does not settle approval, but it does make the case stronger. In a population with limited options after anti-PD-1 progression, getting an expert panel to endorse the data as worthwhile is a real shift.

Why investors are repricing the stock now

Replimune has been here before, and two prior rejections still make this story uncertain. But this vote changes the debate. Instead of arguing whether the IGNYTE data deserve serious consideration, investors can focus more directly on whether the FDA is ready to approve based on them.

What the market is pricing after the vote

From "maybe someday" to "maybe soon"

When an FDA panel says data are evaluable and clinically meaningful, investors usually hear a different message: approval may be closer than previously thought. That can drive a rerating even before the agency makes its final call.

Why tumor response matters in this setting

In melanoma patients who have progressed on anti-PD-1 therapy, treatment options are limited. That makes tumor shrinkage more meaningful than it might be in other settings. Reporting from the meeting noted about one-third saw some level of tumor response, and 15% had complete responses. Investors are paying attention because those figures suggest the combination could produce meaningful benefit in a meaningful share of patients.

Why the timing matters more than the story

The FDA tends to follow the recommendations of its expert panels, though it is not bound by them. That leaves enough uncertainty to keep the risk high, but also enough precedent to make approval look more plausible than it did before the meeting. If the FDA approves, Replimune will move from regulatory drama to commercial execution. If it does not, investors may have to look through a longer gap until a confirmatory trial is expected in late 2027.

What still could go wrong with single-arm RP1 data

A favorable vote was still a contested one

The advisory committee's 10-3 vote shows real support, but it also shows that some panelists still had reservations. More important, "evaluable and clinically meaningful" is not the same as conclusive. A single-arm trial can support approval in a high-need setting, but it still has to answer the FDA's core question: is the benefit real, durable, and attributable to the treatment being reviewed?

The main watchpoints remain real

Bulls argue that tumor shrinkage is enough to justify access in a population with few options. Bears argue that without a control arm, the data still cannot fully separate RP1's contribution from nivolumab. That is why gains after a panel win can still be reversed: the scientific debate was not settled, only carried into the final review stage.

What REPL holders should watch before Aug. 2

This rally looks reasonable, not extreme. The panel has already signaled that it finds the data evaluable and clinically meaningful, and the FDA now has a Aug. 2 decision date to deliver a yes-or-no answer.

Approval or another rejection

• Approval: the stock would then have to shift from event-driven trading to a commercial narrative around adoption, access, and real-world utility.
• Refusal: the bear case would re-emerge sharply, pushing investors back toward a longer timeline that includes a confirmatory trial expected in late 2027.

For now, the move reflects a simple idea: the panel has done some of the heavy lifting, and the FDA's decision is now the next real catalyst.